Dr. David Samadi is the chairman of Urology and the Chief of robotic Surgery at Lenox Hill Hospital. Dr. Samadi is a celebrated doctor that is also certified by the board of urology. Dr. Samadi has been traoned in the treatment and diagnosis of prostate cancer, kidney cancer, bladder cancer and other urologic diseases. He has a specialty in minimally invasive prostate cancer treatments that are advanced. These treatments include laparoscopic robotic radical prostatectomy, and laparoscopic radial prostatectomy.
Dr. Samadi was born and raised in Iran in the Persian Jewish community. Samadi left Iran at the age of 15 along with his younger brother in 1979 following the Iranian Revolution. Both of their educations were continued in London and Belgium. Afterwards, Samadi came to the United States of America in order to attend and complete high school in Roslyn, New York. Stony Brook University is where Dr. David Samadi completed a full scholarship where he earned his biochemistry degree. His M.D. was earned at S.U.N.Y. which is the Stony Brook School of Medicine. This school is located in Stony Brook, New York. Dr. David Samadi earned his M.D. in 1994.
Dr. Samadi’s postgraduate training in urology took place at Montefiore Medical Center. His training in proctology took place at Albert Einstein College of Medicine. One of these trainings were completed in 1996. One was completed in 2000. A proctology oncology fellowship was completed by Dr. Samadi in the year 2001. The oncology fellowship took place at Memorial Sloan Kettering Cancer Center. Dr. Samadi completed a robotic radical prostatectomy fellowship in 2002 under the mentorship of Professor Claude Abbou. This took place at Henri Mondor Hospital Creteil. Mondor Hospital Creteil is located in France.
In 2012, Dr. David Samadi was the highest paid doctor in New York City. Dr. Samadi’s earned totaled $7.6 million. Before then, Dr. Samadi was employed at Mt. Sinai School of Medicine in 2007. Samadi became the chief of Robotics and Minimally Invasive Surgery and the Vice Chair of the Department of Urology. Before then was his very first practice which took place at Columbia Presbyterian Hospital.
Cancer Treatment Centers of America is often at the forefront of new cancer news. Recently, this revered cancer care center teamed forces with Labcorp staff and NFL Alumni Organization concerned members to highlight that prostate cancer is deadly if not treated early. They offered free complimentary prostate cancer screenings to shine a spotlight on the need for early intervention through available cancer screens and testing. As more men get regular routine prostate screens, these high mortality rates are beginning to decline. With an increase in elderly people living to advanced ages, it is more important than ever to encourage more cancer screening participation.
Prostate cancer can lurk for years silently invading healthy tissues of men across the world. There are certain races that have even higher rates of documented prostate cancer occurrence. Those at Cancer Treatment Centers of America continue to sound the alarm to other healthcare providers and the ordinary citizen about the potential for prostate cancer deaths. With the turn towards preventative health measures being more accepted by medical insurance companies and the general public, it is hoped that this deadly disease will continue to decline as more men get tested in time for successful treatment.
Cancer Treatment Centers of America often are one of the first leading healthcare institutions to embrace a brand new cancer care find. This could be new drug combination possibilities, more targeted radiation or other technological treatment or a new benefit that a specific diet food can bring. This specialized treatment center recognizes that many things can lead to a cancer remission break or a cure. This is one reason why Cancer Treatment Centers of America heavily promotes new research and participates in many promising clinical cancer treatment trials. Cancer Treatment Centers of America encourages new ideas on how to best treat cancer.
Everyone in the medical world agrees that cancer is one of the diseases that have been a menace in the past few decades. The fact that the therapies which have been developed to manage the cases of cancer are only effective when the tumors haven’t spread for long makes treatment a tricky business. However, there are a few researchers who have been trying their best to transform the manner in which cancer treatment is done; and Clay Siegall is one of them. Clay is the co-founder, president, and CEO of Seattle Genetics.
Clay Siegall founded Seattle Genetics in 1998. When he started the company, his dream was to get a cancer treatment or therapies that could work in suppressing cancerous growths, without a lot of side effects. When he started the laboratory, he had very limited resources. The company got their breakthrough when the FDA approved one of the drugs they had been working on ADCETRIS, for the treatment of cancer. For the past six years, the company has been trading on NASDAQ under the name of SGEN.
The company is now looking forward towards getting some other drugs that they have been working on approved by the FDA. They plan to employ more technicians and expand their laboratories to expedite their research. Their pioneer drug, ADCETRIS is currently on sale in more than 66 countries and has placed the company on the global map for the creation of useful therapies for multiple lymphomas. Under the leadership of Clay Siegall, Seattle Genetics has raised more than $1.2billion, both in public and private fundraising. He admits that without this financial support, the company might not have achieved the success that they are enjoying now.
When he was asked whether he is thinking about selling the company to the big Pharma like most of the other clinical trial companies do after striking it big, Clay stated that Seattle Genetics is here to stay. He added that they pulled through it when things were so tight that they didn’t even have enough money to pay their employees, and they are in no way planning to give the company up now.
Eric Lefkofsky is an American entrepreneur who was born in Detroit, Michigan. He was born in September of 1969 to his dad who was a structural engineer and his mom who was a school teacher. He is currently chairman of Groupon and also the co-founder and CEO of Tempus.
Eric Lefkofsky grew up in the Southfield, Michigan area. He attended the local schools and graduated from the Southfield-Lathrup high school in 1987. After attending local high school Lefkofsky then went on to attend the University of Michigan. He graduated in 1991 with high honors before moving on to continue his education.
After graduating from the University of Michigan in 1991 Eric Lefkofsky then went on to attend the University of Michigan Law School located in Ann Arbor, Michigan. The law school was founded in 1859 and is one of the top law schools in the U.S. He eventually graduated receiving his Juris doctor in 1993.
Upon completing his education at the University of Michigan law school Eric Lefkofsky went on to work for a variety of different companies. He is currently the chairman as well as the co-founder of the e-commerce website Groupon. He is also the co-founder and CEO of Tempus which is a new and innovative way to treat cancer patients.
Eric Lefkofsky also co-founded Echo Global Logistics in 2005. It is a freight logistics company that is currently headquartered out of Chicago, Illinois. Eric Lefkofsky co founded Mediaocean. Mediaocean was first founded in 2012 and is an advertising firm that currently has over 800 employees.
These are just a few of the many different companies that Eric Lefkofsky has worked for or co-founded. He is also involved in many different philanthropic endeavors including The Giving Pledge as well as his own foundation The Lefkofsky Foundation which he started back in 2006 with his wife Elizabeth. It focuses on changing the lives and direction of children. It has currently helpef fund more than 50 different organizations all around the world.
Eric Lefkofsky is an American based businessman and Philanthropist. He is the founder and president of Tempus, an organization that seeks to compile genomic data that aids in clinical development and settings. Eric has participated in the foundation and development of several institutions. He is the chairman at Groupon, the co- founder of Echo Global Logistics, InnerWorking, Mediaocean, and Uptake. Additionally, Eric is the co-founder of a Chicago-based Venture called Lightbank. He is the son of Bill, a structural engineer and Sandy, a school teacher. Eric grew up in Michigan and schooled at Lathrup High School. Later, he furthered his studies at the University of Michigan and graduated in 1991. He proceeded to University of Michigan Law School and attained his doctorate in 1993.
Tempus is an institution that seeks to improve the patient outcomes. Since its inception, the company has set out to redefine how genomic data and sequencing is used in clinical setups. By compiling data and storing in their database, the institution seeks to help patients to benefit from the experience of other treated patients. The patients will receive better care from the physicians as they will be provided with the right tools acquired during genomic data collection.
The Lefkofsky Family Foundation was founded by Eric and his wife, Liz. The foundation seeks to enhance the quality of life by focusing on the following areas.
Education- the Foundation believe in quality education has enabled them to support and strengthen the public schools. As most of the children attend these schools, it ensures that each and every child is awarded the same opportunity. The foundation also engages in initiatives that advance equal education.
Fundamental Human Rights- Over the years, the family foundation has continually advocated for human rights. It has participated in initiatives that foster human dignity and wellbeing and consequently, improving the quality of life.
Medical Research- the Foundation funds several research facilities with the aim of boosting medical research that cures diseases. In several occasions, the foundation has donated to cancer research centers.
Arts and Culture- the institution supports a broad range of cultural programs that enhance creativity and boosts talent. Usually, their aim is to enrich the local communities.
Among the many companies that have delved into cancer research over the last one to two decades, Seattle Genetics stands out as the leading company when it comes to innovation and expertise. At the center of the company’s excellence is Dr. Clay Siegall, its CEO of the last 15 years. Under the leadership of Siegall, who is also the firm’s president and board chairman, Seattle Genetics has witnessed massive advancements in cancer research, including developing several cancer therapies for those battling the life-threatening disease. Among the notable of these therapies include ADCETRIS®, an FDA-approved antibody drug conjugate. Consequently, its products are dominating markets in over 60 countries, with the stock tripling over a period of not more than five years.
Dr. Clay Siegall is a very accomplished man, with his experience in Genetics spanning over two decades. His first accomplishment was successful completion of a Ph.D. in Genetics from the internationally celebrated George Washington University. Equipped with his Ph.D., Siegall kicked off what would later turn out to be an excellent career at the Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator. Following a thorough service in the position, he earned a promotion to the rank of principal scientist. At this point, Siegall had already made a name for himself, and it was just a matter of few years before National Cancer Institute hired him to serve as a biotechnology fellow. Having accumulated all this experience, he set off on his own to establish Seattle Genetics.
More about Siegall
Siegall’s brilliance extends beyond cancer research. He has in the past shown great mobilization skills by single-handedly fundraising funds for his company to the tune of $1.2 billion. He is also a prolific scientific publisher, with about 70 articles and 15 patents to his name. In a nutshell, Siegall is not just helping patients; he is also aiding future research by these publications.
On March 28, 2016, Bizjournal reported that Clay Siegall and Seattle Genetics were on the verge of hiring an extra 350 employees. Siegall had revealed to the journal that 120 employees would be hired within that year, with 100 of them working in the U.S. and the rest in Switzerland.